Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)

Recruiting now

Conditions studied: Metastatic Castration-resistant Prostate Cancer

In brief

PROceed is a multisite, prospective, observational study that describes the real-world use and clinical experience of mCRPC patients treated with the combination of olaparib and abiraterone in the mCRPC setting. Clinical outcomes will be assessed in patients who are either NHA-naive or NHA-exposed prior to initiating olaparib + abiraterone treatment, respectively. Patient demographic and clinical characteristics, as well as treatment received prior and subsequent to olaparib + abiraterone, will also be described. The study plans to enroll patients for a maximum of 2 years and follow up patients from initiation of olaparib until 1 year post last patient in.

Key facts

Study ID

NCT06380738

Run by

AstraZeneca

People needed

250

Starts

2024-02-14

Expected to finish

2027-02-14

Last updated by the study team

2026-07-17

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Willing and able to provide written informed consent;
• 18 years of age and above;
• Documented histopathology or cytopathology of PCa, adenocarcinoma;
• Confirmed as mCRPC;
• Initiated olaparib + abiraterone after site activation

You may not qualify if…

• Patients participating in a clinical trial with an investigational prostate cancer treatment within 30 days prior to olaparib initiation

Where it is running

• Research Site — Aschaffenburg, Germany (enrolling)
• Research Site — Augsburg, Germany (enrolling)
• Research Site — Bergisch Gladbach, Germany (enrolling)
• Research Site — Berlin, Germany (enrolling)
• Research Site — Bonn, Germany (enrolling)
• Research Site — Cologne, Germany (enrolling)
• Research Site — Dresden, Germany (enrolling)
• Research Site — Duisburg, Germany (enrolling)
• Research Site — Eisenach, Germany (enrolling)
• Research Site — Eisleben Lutherstadt, Germany (enrolling)
• Research Site — Frankfurt, Germany (enrolling)
• Research Site — Greifswald, Germany (enrolling)
• Research Site — Halle, Germany (enrolling)
• Research Site — Hamburg, Germany (enrolling)
• Research Site — Hanover, Germany (enrolling)
• Research Site — Heidelberg, Germany (enrolling)
• Research Site — Heinsberg, Germany (enrolling)
• Research Site — Herzogenaurach, Germany (enrolling)
• Research Site — Leipzig, Germany (enrolling)
• Research Site — Lübeck, Germany (enrolling)
• Research Site — Lüneburg, Germany (enrolling)
• Research Site — Magdeburg, Germany (enrolling)
• Research Site — Marburg, Germany (enrolling)
• Research Site — Mülheim, Germany (enrolling)
• Research Site — Münster, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.